Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:EU Recommendations of the expert group - Risk proportionate approaches in clinical trials 25-Apr-2017 4.1: Difference between revisions

From GxPlex

Jump to: navigation, search
← Older editNewer edit →
gxplex>GxPlexBot
Import from GxPlex Excel
Migrate to Template:ReferenceData for PageForms (GxPlexBot)
Line 1: Line 1:
{{#set:
{{ReferenceData
|HasDocument=Document:EU Recommendations of the expert group - Risk proportionate approaches in clinical trials 25-Apr-2017
|has_document=Document:EU Recommendations of the expert group - Risk proportionate approaches in clinical trials 25-Apr-2017
|RefScope=HM
|module=1
|RefDocPart=4.1
|unit=1.2.7
|RefLanguage=EN
|scope=HM
|RefTags=TAG-00289-Ris-Qua ++ TAG-00288-Qua-nag ++ TAG-00176-Ris-erh
|doc_part=4.1
|RefModule=1
|language=EN
|RefUnit=1.2.7
|entry_by=Florian Adragna
}}
|contributors=
 
|tags=TAG-00289-Ris-Qua ++ TAG-00288-Qua-nag ++ TAG-00176-Ris-erh
{{:Document:EU Recommendations of the expert group - Risk proportionate approaches in clinical trials 25-Apr-2017}}
|tags_display=[[Glossary:TAG-00289-Ris-Qua|Risk-based quality management]], [[Glossary:TAG-00288-Qua-nag|Quality management system]], [[Glossary:TAG-00176-Ris-erh|Risk]]
 
|comment=Risk-based quality management system for clinical trials
{| class="wikitable gplx-infobox"
|content=A risk based quality management system for clinical trials should include the following steps:
|-
! colspan="2" class="gplx-infobox-header" | Reference Details
|-
! Module
| Module 1 — Unit 1.2.7
|-
! Scope
| HM
|-
! Document part
| 4.1
|-
! Language
| EN
|-
! Original entry by
| Florian Adragna
|-
! Contributors
|
|-
! Tags
| [[Glossary:TAG-00289-Ris-Qua|Risk-based quality management]], [[Glossary:TAG-00288-Qua-nag|Quality management system]], [[Glossary:TAG-00176-Ris-erh|Risk]]
|-
! Comment
| Risk-based quality management system for clinical trials
|}
 
== Content ==
A risk based quality management system for clinical trials should include the following steps:
- critical process and data identification
- critical process and data identification
- risk identification
- risk identification
Line 49: Line 19:
- risk review
- risk review
- risk reporting
- risk reporting
}}

Revision as of 12:55, 16 July 2026



Document information
Reference EU Recommendations of the expert group -

Risk proportionate approaches in clinical trials 25-Apr-2017

Validity area EU
Scope(s) HM
Document name Recommendations of the expert group -

Risk proportionate approaches in clinical trials

Version / Revision 25-Apr-2017
Status Current
Document type Official recommendation
Language(s) EN
Description Risk proportionate approaches in clinical trials

Recommendations of the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use

Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 1 — Unit 1.2.7
Scope HM
Document part 4.1
Language EN
Original entry by Florian Adragna
Contributors
Tags Risk-based quality management, Quality management system, Risk

Content

A risk based quality management system for clinical trials should include the following steps: - critical process and data identification - risk identification - risk evaluation - risk control - risk communication - risk review - risk reporting

Retrieved from "https://gxplex.org/index.php?title=Reference:EU_Recommendations_of_the_expert_group_-_Risk_proportionate_approaches_in_clinical_trials_25-Apr-2017_4.1&oldid=16155"